[Alzheimer disease: efficacy and tolerance of rivastagmine].
Hébert
M
M
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D015337:Multicenter Studies as Topic; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048448:Phenylcarbamates; D016032:Randomized Controlled Trials as Topic; D000068836:Rivastigmine
D002219:Carbamates; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine